Remicade® infliximab

Find a Specialist | Contact Us | For Healthcare Professionals

Psoriasis
Rheumatoid Arthritis
Psoriatic Arthritis
Crohn's Disease in Adults
REMICADE for Crohn's
Pediatric Crohn's Disease
Ulcerative Colitis
Ankylosing Spondylitis
Important Safety Information



 

REMICADE for Crohn’s in Adults

Resource Center
Crohns Control Quiz
Medical Specialist Locator
Inside Crohn's Interactive Video
REMICADE News
and Updates

Crohn's putting your life on hold? Help put flare-ups on hold.

If you have moderate to severe Crohn’s and have tried other therapies without success, REMICADE may be able to help keep your Crohn’s under control.

  • REMICADE helps put Crohn’s into remission and relieves symptoms by binding and blocking the effects of TNF-alpha, a protein involved in the inflammation process.
  • Many patients have achieved response in as little as two weeks and continue to have freedom from flare-ups through ongoing therapy.
  • REMICADE may also help you reduce or stop steroid use. Only your gastroenterologist can decide whether reducing or stopping steroids is appropriate for you.
  • A 54-week medical study showed that when REMICADE is given as maintenance therapy, one out of every four patients (who were taking steroids) was able to achieve remission and discontinue steroids, compared to approximately one out of every ten patients who received a single infusion of REMICADE.
  • REMICADE is for patients with moderate to severe Crohn's whose disease is still active despite treatment with other therapies.
  • REMICADE is not for everyone. Individual results may vary. Please read Important Safety Information below and the Medication Guide for REMICADE and discuss with your doctor.

For further information about studies involving REMICADE and Crohn’s disease, please visit the following resource:


IMPORTANT SAFETY INFORMATION | Privacy Policy | Legal Notice | Site Map | About Centocor Ortho Biotech Inc.

© Centocor Ortho Biotech Inc. 1999-2009
This site is published by Centocor Ortho Biotech Inc. which is solely responsible for its contents.
It is intended for residents from the United States.
Last Updated: January 19, 2009